Sonde Health purchases NeuroLex Labs’ voice platform and 500K biometric samples
Sonde Health acquires NeuroLex Laboratories, Inc. to forms one of the world’s preeminent biobanks focused on vocal biomarkers
NeuroLex’s core product, SurveyLex, makes it easy to create and distribute voice surveys in less than a minute as URL links through web browsers
Boston, 25 August 2020: Sonde-Health, a Boston-based digital vocal biomarker technology platform announced it has acquired NeuroLex Laboratories, Inc., a leading voice-enabled survey and data acquisition platform. The acquisition brings together two of the leading forces in the vocal biomarker space.
Sonde will acquire NeuroLex’s popular web-enabled voice survey and analysis platform, as well as its rich dataset, which when combined with Sonde’s leading voice-based dataset, forms one of the world’s preeminent biobanks focused on vocal biomarkers. In addition, merging Sonde’s mobile and voice-assistant platforms with NeuroLex’s web-based capabilities will enable the delivery of voice-enabled heath detection and monitoring over any platform.
Democratizing Voice Computing
Over the past two years, NeuroLex has built one of the largest laboratories in the world to collect, label, and model voice data tagged with health conditions comprised of over 40 research fellows across 12 universities that have published over 5 peer-reviewed journal articles. NeuroLex’s core product, SurveyLex, makes it easy to create and distribute voice surveys in less than a minute as URL links through web browsers. With this product, NeuroLex has curated a biobank comprised of over 500,000 voice samples from over 30,000 individuals alongside a host of pharmaceutical and academic partners.
Acquisition Benefits for Sonde
“At Sonde, we have unlocked voice as a new vital sign to enable secure, accessible, and non-intrusive monitoring of health. Incorporating NeuroLex’s impressive work in voice-based surveys and research moves us significantly forward in becoming the one-stop shop for health condition detection and monitoring through voice,” said David Liu, CEO of Sonde Health. “NeuroLex’s voice-based survey platform and biobank will accelerate our research and development, and our collection and analysis of high-quality voice data, bolstering all the products we provide to our customers.”
Sonde’s proprietary technology works by sensing and analyzing subtle changes in the voice due to changes in a person’s physiology. The company’s respiratory and depression health checks are available today.
As part of the acquisition, Jim Schwoebel, the chief executive officer of NeuroLex, will join Sonde’s leadership team as Vice President, Data and Research.
“I am thrilled to bring Jim and his team on board,” continued Liu. “His experience in building NeuroLex, shared mission of using vocal biomarkers to move healthcare forward, and expertise in building large voice-based datasets and machine learning make Jim a tremendous addition to the Sonde team.”
Financial details of the acquisition were not disclosed.